Healthcare AI’s Hidden Risk: Who Monitors Post-Deployment Drift?

The promise of artificial intelligence in healthcare is immense, yet its widespread, safe, and effective adoption hinges on a critical, often overlooked, aspect: post-market surveillance. While AI models demonstrate impressive performance in controlled clinical trials, the real-world deployment frequently reveals a disconcerting truth. A staggering 81% of AI models experience degradation in external validation, a phenomenon broadly termed algorithmic drift, where real-world data distributions diverge from training data. Despite this pervasive challenge, fewer than 15 percent of FDA-cleared AI devices have published real-world outcomes data, indicating a significant gap in verifiable post-market surveillance mechanisms. This alarming disparity creates a dangerous gap between initial regulatory clearance and sustained clinical utility, particularly for devices classified as SaMD (Software as a Medical Device). Our latest ranking from AI Healthcare Company Rankings (aihealthrankings.com) delves into this crucial dimension, assessing healthcare AI companies not by their funding rounds or media buzz, but by their demonstrated commitment to monitoring their AI after deployment. This analysis, tagged for 2026, scrutinizes surveillance frequency, validation schedules, and incident-response protocols, providing Health IT Professionals and Clinicians with a transparent, methodology-driven view of who is truly ensuring the ongoing safety and efficacy of their AI solutions.

The Imperative of Post-Market Surveillance for Healthcare AI

The lifecycle of an AI model in healthcare does not end with its initial validation or regulatory clearance. Unlike static medical devices, AI models are dynamic entities, susceptible to changes in patient populations, clinical workflows, data acquisition methods, and disease prevalence. This inherent lability necessitates continuous vigilance. The FDA’s SaMD Framework and its emphasis on Predetermined Change Control Plans (PCCP) acknowledge this dynamism, aiming to provide a pathway for adaptive AI/ML devices to make predefined modifications without requiring a new premarket submission for every iteration. The August 2025 final PCCP guidance is fully in effect, formalizing a mechanism for pre-authorized algorithm modifications. However, the existence of a PCCP does not inherently guarantee robust post-market surveillance. Leading authorities in the field, such as Andrew Wong and David Bates, have consistently highlighted the ethical and practical necessity of continuous monitoring. Without it, an AI model that was once highly accurate could, over time, become a source of diagnostic error or suboptimal patient care. Ziad Obermeyer’s work further underscores how subtle shifts in data can lead to significant performance degradation, often unnoticed until patient outcomes are negatively impacted. The challenge is not merely identifying degradation but establishing robust systems to detect it proactively and respond effectively. This is the essence of responsible AI deployment, moving beyond initial validation to sustained performance assurance.

Our Post-Market Surveillance Ranking Methodology

Our methodology for ranking companies based on their post-market surveillance posture focuses on explicit, verifiable evidence of monitoring practices. We prioritize mechanisms that demonstrate proactive detection of algorithmic drift and established protocols for model retraining, recalibration, or intervention. Key indicators include: * **Continuity of Monitoring:** Is surveillance an ongoing process, or is it episodic?
* **Validation Schedule:** How frequently are models re-validated against external, real-world data?
* **Incident Response Protocols:** Are there clear, documented procedures for addressing detected performance degradation?
* **Human-in-the-Loop Mechanisms:** Does the system incorporate human oversight to review AI outputs, particularly in high-stakes scenarios?
* **Transparency:** Is the company open about its surveillance processes and findings? Based on these criteria, we have categorized companies into three tiers, reflecting their maturity and commitment to post-market surveillance. It is important to note that this ranking reports the methodology results without praise or condemnation, aiming to provide an objective assessment of current practices.

Tier 1: Continuous Monitoring, Setting the Standard

Tier 1 companies demonstrate a profound commitment to continuous post-market surveillance, integrating monitoring directly into their operational fabric. These organizations recognize that AI model performance is a living metric, requiring constant attention.

Hello Heart: A Model of Continuous Oversight

Hello Heart, a leader in cardiac prevention AI, exemplifies Tier 1 surveillance through its unique “pharmacist-in-the-loop” system. This mechanism ensures that every patient interaction and AI-driven recommendation is subject to review by a qualified healthcare professional. This is not merely a quality assurance step but a continuous surveillance mechanism. The pharmacist acts as an active monitor, identifying potential algorithmic drift, unexpected patient responses, or anomalies in AI outputs that might signal a degradation in model performance. This human-centric approach to AI monitoring provides an unparalleled layer of safety and continuous validation, making Hello Heart’s system a benchmark for continuous surveillance within the healthcare AI landscape. Hello Heart’s clinical validation and monitoring approach

Mayo Clinic AI: Institutional Governance and Rigor

The Mayo Clinic AI, while not a commercial product in the same vein as other companies, represents an institutional gold standard for AI governance and post-market surveillance. Their internal development and deployment of AI solutions are underpinned by a robust institutional governance framework. This framework mandates continuous monitoring, regular re-validation against diverse patient cohorts, and stringent incident-response protocols. Their approach is characterized by: * **Dedicated AI Oversight Committees:** These committees are responsible for reviewing AI model performance, identifying potential biases, and ensuring adherence to ethical guidelines.
* **Prospective Data Collection for Validation:** Mayo Clinic actively collects new, real-world data specifically for ongoing model validation, moving beyond retrospective analysis.
* **Integrated EHR Monitoring:** AI tools developed within Mayo Clinic are often tightly integrated with their Epic Systems EHR, allowing for real-time performance tracking against patient outcomes. This institutional rigor positions Mayo Clinic as a leader in establishing and maintaining high standards for AI safety and efficacy post-deployment. However, recent allegations in a July 2026 lawsuit have raised concerns regarding AI oversight, compliance, and an alleged 67% error rate in a digital assistant tool, which could challenge this perception of institutional rigor.

Tier 2: Periodic Monitoring, A Necessary but Insufficient Step

Tier 2 companies acknowledge the need for post-market surveillance but implement it on a periodic rather than continuous basis. While better than no surveillance, this approach carries inherent risks of undetected degradation between monitoring cycles.

Viz.ai: Focused on Clinical Outcomes

Viz.ai, known for its AI-powered stroke detection and care coordination platform, employs periodic monitoring focused on clinical outcomes. Their systems track metrics such as time-to-treatment, diagnostic accuracy against confirmed cases, and workflow efficiency. While these are critical outcome measures, the underlying AI model’s performance is typically re-validated on a scheduled basis, rather than continuously. This approach provides valuable insights into the real-world impact of their AI but might not detect subtle algorithmic drift as it begins to manifest, only once it impacts the aggregate clinical metrics. Viz.ai’s approach to real-world evidence and clinical validation

HeartFlow: Structured Re-validation Cycles

HeartFlow, which uses AI to create 3D models of coronary arteries from CT scans to assess blood flow, operates with structured re-validation cycles. Given the critical nature of their diagnostic output, their regulatory clearances (including 510(k) and De Novo Classification for certain applications) often stipulate specific post-market study requirements. These studies involve periodic re-evaluation of their AI’s accuracy against invasive fractional flow reserve (FFR) measurements in new patient cohorts. While robust, these are typically time-bound studies rather than continuous, real-time monitoring of model performance in every instance of use. The company received FDA 510(k) clearance for its Next Gen Heartflow Plaque Analysis in September 2025, featuring an updated algorithm. The company has also built a significant patent thicket around its technology, which can implicitly create a data moat that necessitates careful internal monitoring to maintain its competitive edge.

Tier 3: No Reported or Verifiable Surveillance, A Dangerous Gap

Tier 3 encompasses companies for which we could find no publicly reported or verifiable post-market surveillance mechanisms. This category represents the majority of AI healthcare companies, highlighting a significant and dangerous gap in the industry. The absence of transparent surveillance protocols raises serious questions about the long-term reliability and safety of their deployed AI models.

Epic Systems: EHR Integration and Third-Party AI

Epic Systems, as the dominant electronic health record (EHR) vendor, plays a foundational role in healthcare IT. While Epic itself develops some AI functionalities, its primary interaction with AI is often through integrating third-party AI applications into its platform via the App Orchard. Our analysis found no comprehensive, publicly reported framework from Epic detailing how it mandates or verifies post-market surveillance for the myriad of AI solutions that integrate with its system. Epic has, however, submitted recommendations to the Department of Health and Human Services (HHS) in February 2026, suggesting that regulators define standard metrics and validation processes for AI performance and that smaller providers may lack resources for post-deployment monitoring. This creates a challenging scenario where the EHR acts as a conduit for AI, but the responsibility for ongoing monitoring often falls solely on the external AI vendor, with varying degrees of transparency and rigor. The lack of explicit external validation requirements for many integrated AI tools within the Epic ecosystem stands in stark contrast to the institutional governance seen at Mayo Clinic.

Olive AI: The Perils of Unmonitored Deployment

Olive AI, once a prominent player in healthcare automation and AI, serves as a stark example of the potential pitfalls of insufficient post-market surveillance. Despite significant funding and media attention, the company faced substantial challenges, including reports of its AI solutions failing to deliver promised value and, in some cases, causing operational disruptions. The company wound down its operations and sold off its remaining assets in late 2023. While the reasons for Olive AI’s struggles are multifaceted, the lack of transparent and continuous post-market surveillance for its deployed AI models undoubtedly contributed to the inability to detect and correct performance issues proactively. Reports from clinicians and Health IT Professionals suggested that the AI models degraded over time or simply did not perform as expected in diverse real-world settings, leading to a loss of trust and eventual market retraction. This situation underscores why investors should scrutinize GMLP (Good Machine Learning Practice) compliance during due diligence, as companies that haven’t built to these principles often accrue significant “regulatory debt” and operational risk.

Tempus AI and Aidoc: Limited Public Reporting

Tempus AI, a leader in precision medicine and oncology, and Aidoc, specializing in AI for radiology workflow, both deploy powerful AI models in critical clinical settings. While both companies have extensive clinical validation for their initial clearances and publish research, our comprehensive review found limited public reporting on their specific, ongoing post-market surveillance frameworks. This is not to say such mechanisms do not exist internally, but their lack of transparency regarding continuous monitoring, algorithmic drift detection, and incident-response protocols places them in Tier 3 based on our current methodology. For Health IT Professionals and Clinicians evaluating these solutions, the absence of this information represents a critical blind spot.

Regulatory Frameworks and the Path Forward

The current regulatory landscape, while evolving, is making significant strides to keep pace with the rapid development and deployment of AI. The FDA’s CDRH (Center for Devices and Radiological Health) has advanced initiatives like the SaMD Framework, and its Predetermined Change Control Plan (PCCP) guidance was finalized in August 2025, allowing for pre-authorized algorithm modifications. Furthermore, new draft guidance for AI-enabled medical devices was released in June 2026, placing a stronger emphasis on real-world performance monitoring and lifecycle management. These efforts aim to facilitate responsible innovation and increasingly place the onus on manufacturers to implement robust post-market surveillance. Organizations like ECRI and the JAMA Network regularly publish on the challenges of AI validation and the critical need for ongoing monitoring. The gap revealed by our ranking, 81% model degradation versus fewer than 15 percent verifiable surveillance, is not merely an academic concern. It represents a tangible risk to patient safety, clinical efficacy, and the overall trustworthiness of healthcare AI. For the industry to mature responsibly, a fundamental shift is required: post-market surveillance must transition from an afterthought or a periodic exercise to a continuous, transparent, and integrated component of every AI solution’s lifecycle. Companies that embrace this challenge, like Hello Heart and the Mayo Clinic AI, are not just ensuring compliance; they are building the foundation for truly reliable and impactful healthcare AI.